Upstream Triggers: Respiratory Chain Disruption, Iron Dysregulation, and Radical Generation
Doxorubicin accumulation in cardiac tissue initiates pronounced cardiotoxicity via genomic and mitochondrial target engagement [1][2]. Following cellular entry, doxorubicin intercalates into DNA and stabilizes cleavable complexes with topoisomerase IIβ, suppressing mitochondrial genome-encoded transcripts, including ND1, ND4, and COX1 [1][3]. Within the inner mitochondrial membrane, the quinone moiety of doxorubicin undergoes univalent reduction at respiratory complex I, generating steady fluxes of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂) [2][4]. This persistent electron leakage impairs the activity of respiratory chain complexes I, II, and IV [2]. Concomitant dysregulation of iron-regulatory proteins precipitates mitochondrial iron overload, driving Fenton-mediated generation of highly reactive hydroxyl radicals (^{\bulletOH}) [1][4]. The resulting oxidative environment oxidizes cardiolipin, a phospholipid essential for anchoring cytochrome c, initiating organellar outer membrane permeabilization in H9c2 cardiomyoblasts and adult ventricular myocytes [1][5].
These primary biochemical insults impair organelle ultrastructure, altering dynamic structural remodeling proteins and precipitating cardiomyocyte metabolic exhaustion across experimental systems [1][3].
Drp1 Post-Translational Activation and Assembly at the Outer Mitochondrial Membrane
The morphological shift toward mitochondrial fragmentation is executed by dynamin-related protein 1 (Drp1) [1][2]. Doxorubicin exposure stimulates intracellular calcium (Ca²⁺) transients, which activate the serine/threonine phosphatase calcineurin to dephosphorylate Drp1 at its inhibitory Ser637 residue [1][4]. Concurrently, upstream stress-activated kinases, including CDK1 and ERK2, phosphorylate Drp1 at the pro-fission Ser616 site [1][2]. This dual post-translational modification shifts cytosolic Drp1 from an inactive dimer/tetramer equilibrium into an active assembly-competent state [1][3].
Activated Drp1 shuttles to the outer mitochondrial membrane (OMM), docking onto specific receptor complexes, primarily mitochondrial fission factor (Mff), mitochondrial dynamic proteins of 49 and 51 kDa (MiD49/51), and fission 1 protein (Fis1) [1][3]. In Sprague-Dawley rat models receiving cumulative doxorubicin regimens of 12 mg/kg, cardiac tissue exhibits significant upregulation of Fis1 alongside enhanced Drp1 Ser616 phosphorylation [3]. Upon receptor engagement, Drp1 multimerizes into high-molecular-weight ring-like oligomers circumscribing mitochondrial tubules [1]. Subsequent GTP hydrolysis generates mechanical constriction forces, driving OMM and inner mitochondrial membrane (IMM) scission [1][5]. Pathological Drp1 hyperactivation disrupts the balance between fission and fusion, producing spherical, uncoupled organelles lacking reticular continuity in human iPSC-derived cardiomyocytes [6].
Repression of Mitofusins and Opa1 Cleavage: Imbalance of Fusion Machinery
Hyperactive fission is exacerbated by the coordinated shutdown of the mitochondrial fusion machinery [1][3]. Mitochondrial fusion requires coordinated outer membrane tethering by Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2), followed by optic atrophy 1 (Opa1)-mediated inner membrane coalescence [1]. In AC16 cardiomyocytes, doxorubicin exposure drives rapid proteasomal clearance of Mfn2, leaving Mfn1 unable to preserve network architecture [3][5]. Doxorubicin accelerates the recruitment of E3 ubiquitin ligases, such as Parkin, to the outer mitochondrial membrane, promoting polyubiquitination and 26S proteasome-dependent degradation of Mfn2 [1][3].
Concurrently, inner membrane integrity is destabilized via proteolytic inactivation of Opa1 [1]. Under physiological conditions, long Opa1 (L-Opa1) forms oligomers that maintain cristae junction narrowness and drive inner membrane fusion [1]. Doxorubicin-induced mitochondrial reactive oxygen species and matrix Ca²⁺ overload activate the IMM-resident stress-sensitive metalloproteinase OMA1 [1][4]. OMA1 catalyzes the cleavage of L-Opa1 into short, soluble fragments (S-Opa1) [1]. Accumulation of S-Opa1 disrupts fusion-competent L-Opa1 complexes, widening cristae junctions and halting inner membrane remodeling [1]. In Sprague-Dawley rat myocardium, this imbalance collapses mitochondrial aspect ratios below 1.5, transforming elongated mitochondrial networks into isolated spherical puncta with blunted functional reserve [3].
Bioenergetic Collapse: mPTP Induction, Membrane Potential Loss, and Respiratory Arrest
Structural fragmentation directly couples to mitochondrial bioenergetic collapse [1][2]. Unrestrained Drp1-mediated fission, high reactive oxygen species levels, and elevated matrix Ca²⁺ concentrations converge on cyclophilin D, triggering the sustained opening of the high-conductance mitochondrial permeability transition pore (mPTP) [2][4]. Pore opening allows solutes under 1.5 kDa to equilibrate across the IMM, dissipating the proton motive force [2]. Using TMRM and JC-1 potentiometric probes, rapid dissipation of the mitochondrial membrane potential (ΔΨm) is detectable in cardiomyocytes following doxorubicin incubation [4][7].
Loss of ΔΨm halts rotational catalysis of F_o-F_1 ATP synthase (Complex V) and initiates reverse-mode ATP hydrolysis, rapidly depleting intracellular adenine nucleotide pools [2][7]. Amperometric oxygen consumption rate (OCR) measurements in neonatal rat ventricular myocytes demonstrate severe bioenergetic arrest within 6 h of doxorubicin exposure [7]. Basal respiration, ATP-linked oxygen consumption, and maximal uncoupled respiration decline precipitously following pyruvate/malate or succinate addition [7]. The collapse of prohibitin scaffold complexes in the IMM further destabilizes electron transport chain assembly, consolidating an irreversible bioenergetic defect [2].
Cardiomyocyte Phenotypic Outcomes and Pharmacological Mitigation Strategies
Bioenergetic failure and membrane depolarization culminate in programmed cell death and contractile failure [1][3]. Opening of the mPTP causes outer membrane rupture, extruding cytochrome c and Smac/DIABLO into the cytosol [1][4]. Cytosolic cytochrome c recruits Apaf-1 and dATP to assemble the apoptosome, which cleaves procaspase-9 and activates executioner caspase-3 [1][3]. Caspase-3 cleaves structural sarcomeric proteins, including cardiac troponin T and titin, driving myofilament dissolution [3]. Beyond apoptosis, disrupted mitochondrial-sarcoplasmic reticulum contact sites impair high-energy phosphate delivery to the sarco/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a), impairing diastolic calcium reuptake and causing contractile arrest in H9c2 cells and murine hearts [4][6].
Given the pathogenic role of fission machinery, targeting Drp1 represents an effective strategy to mitigate anthracycline cardiotoxicity [1][5]. Small-molecule inhibition of Drp1 using Mdivi-1 impedes GTPase activity, suppressing Drp1 self-assembly and mitochondrial translocation [1][5]. In AC16 cardiomyocytes and rodent challenge models, Mdivi-1 treatment attenuates mitochondrial fragmentation, prevents ΔΨm dissipation, and suppresses cleaved caspase-3 generation [5]. Similarly, maintaining the Sirt1/Sirt3 axis supports endogenous mitochondrial quality control, sustaining Drp1 Ser637 phosphorylation and elevating SOD2 antioxidant capacity to preserve cardiac performance during anthracycline chemotherapy [1][3].